Pacira BioSciences (PCRX) Cash from Operations Growth (1y) (2011 - 2026)
Pacira BioSciences (PCRX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 90.13 Bn | 88.27 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.48 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 425.00% |
| 10 | Pacira BioSciences | 1.08 Bn | 875.30 Mn | 140.96 Mn | -27.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.58% |
| Dec 31, 2025 | 31.86% |
| Sep 30, 2025 | 12.82% |
| Jun 30, 2025 | -77.44% |
| Mar 31, 2025 | -27.78% |
| Dec 31, 2024 | -30.37% |
| Sep 30, 2024 | 21.34% |
| Jun 30, 2024 | 22.38% |
| Mar 31, 2024 | 156.70% |
| Dec 31, 2023 | 13.20% |
| Sep 30, 2023 | 4.18% |
| Jun 30, 2023 | 45.94% |
| Mar 31, 2023 | -37.85% |
| Dec 31, 2022 | 81.08% |
| Sep 30, 2022 | -29.25% |
| Jun 30, 2022 | -1.09% |
| Mar 31, 2022 | 154.76% |
| Dec 31, 2021 | -50.25% |
| Sep 30, 2021 | 51.55% |
| Jun 30, 2021 | 292.87% |